Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498063 | 0.91 | HRH3 (0.64) | HRH3ALDH1A1MAOBGLAL3MBTL1 | |
| SCHEMBL4622753 | 0.84 | HRH3 (0.66) | HRH3ALDH1A1MAOBGLAL3MBTL1 | |
| SCHEMBL4622140 | 0.84 | HRH3 (0.66) | HRH3GLAL3MBTL1 | |
| SCHEMBL4486761 | 0.83 | HRH3 (0.65) | HRH3ALDH1A1HPGD | |
| SCHEMBL4622153 | 0.82 | HRH3 (0.70) | HRH3 | |
| SCHEMBL4495437 | 0.82 | HRH3 (0.69) | HRH3MAOBGLAL3MBTL1 | |
| Oxalic Acid SCHEMBL4489113 | 0.82 | HRH3 (0.62) | HRH3ALDH1A1GLAL3MBTL1 | |
| Oxalic Acid SCHEMBL4506368 | 0.82 | HRH3 (0.62) | HRH3ALDH1A1GLAL3MBTL1 | |
| SCHEMBL4494595 | 0.81 | HRH3 (0.67) | HRH3MAOB | |
| SCHEMBL5106634 | 0.80 | GLA (0.73) | HRH3ALDH1A1MAOBGLAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576120-B2 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-08-18 | — | — | US | disclosed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | HRH3 9/4885CD274 2669/4885ALDH1A1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.